couter

4584.TKidswell Bio Corporation

Nov 12, 2026 — Q2 2027 Earnings Release
Chart by TradingView

The schedule

  • Thu12Nov

    Kidswell Bio is expected to report Q2 2027 results, providing an update on biosimilar revenues and the accelerating cash burn from clinical R&D.

  • Tue15Dec

    Anticipated Phase 1/2 clinical progress update for the company's proprietary SHED (stem cells from human exfoliated deciduous teeth) therapy.

  • Fri12Feb

    Q3 earnings will serve as a crucial reality check on the balance sheet and cash runway as late-stage R&D scales up.

  • Wed31Mar

    Targeted fiscal year-end timeline for potential new biosimilar out-licensing or contract manufacturing agreements.

  • Thu13May

    Full-year results and initial FY2028 guidance, focusing on the trajectory toward operating profitability.

  • Thu15Jul

    Anticipated regulatory submission of the formal clinical trial plan to the PMDA for corporate-sponsored SHED cell therapy trials.

  • Thu12Aug